Latest News - Pfizer
Top Corporates Hub
Pfizer
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
14.08.2026 05:00
NEW YORK & LYON, France, August 14, 2026--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies’ 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application.
Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
14.08.2026 04:37
Eton Pharmaceuticals Inc (NASDAQ: ETON) rose in pre-market trading after reporting strong Q2 results and issuing FY26 revenue guidance above estimates.
Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ...
13.08.2026 05:01
SPRO strengthens its balance sheet and extends cash runway into 2029 while advancing its new SP001 immunology pipeline following the landmark approval of the first oral carbapenem antibiotic.
Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
13.08.2026 05:00
Total product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash management and proceeds from the recent reserved offering1 Restructuring program implemented with positive P&L and cash flow impacts expected in the second half of the year and beyond Regulatory decisions for Lyme disease vaccine candidate expected in the next twelve months2 Pfizer remains optimistic
5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call
13.08.2026 02:29
Pfizer’s second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company’s performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions from acquired brands and recent launches. CEO Albert Bourla attributed operational progress to “continued strategic progress” and emphasized the value generated by recent acquisitions such as Seagen and Biohaven. Management
Which S&P500 stocks are the most active on Wednesday?
12.08.2026 18:05
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the most active S&P500 stocks in today's session.
10 Health Care Stocks With Whale Alerts In Today’s Session
12.08.2026 13:35
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
Most active S&P500 stocks in Monday's session
10.08.2026 18:05
Looking for the most active stocks in the S&P500 index on Monday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market.
Stock Market Pro Chooses The Best ETFs To Own
07.08.2026 12:01
Volatility in the stock market and the Magnificent Seven dominate the headlines. Investors are repositioning toward more value-based funds.
U.S. CDC Says As Of August 6, 2,465 Confirmed Measles Cases Were Reported In U.S. In 2026; There Have Been 38 New Measles Outbreaks Reported In 2026, And 94% Of Confirmed Cases Are Outbreak-Associated
07.08.2026 11:06
https://www.cdc.gov/measles/data-research/index.html
Global Influenza Vaccine Market Report, 2026 Edition - Profiles GlaxoSmithKline, Pfizer, Sanofi, Moderna, and 9 Other Players
07.08.2026 09:54
Dublin, Aug. 07, 2026 (GLOBE NEWSWIRE) -- The "Global Influenza Vaccine Market: 2026 Edition" has been added to ResearchAndMarkets.com's offering. The global influenza vaccine market was valued at US$8.96 billion in 2024 and is projected to reach US$13.32 billion by 2030, expanding at a compound annual growth rate of approximately 7% between 2025 and 2030. Market growth is being supported by rising public health awareness, an expanding geriatric population, government immunization programs, recu
Pfizer (PFE) Could Be 12% Undervalued Following Raised 2026 Revenue Guidance
06.08.2026 00:17
Pfizer (PFE) is back in focus after its second quarter 2026 update, which paired a reported net loss and sizeable non cash impairments with higher full year revenue guidance and solid non COVID product performance. See our latest analysis for Pfizer. The latest results and raised revenue guidance have lifted sentiment toward Pfizer, with the stock showing a 1 month share price return of 8.81% and a 1 year total shareholder return of 15.42%, although longer term total shareholder returns...
3 Beaten-Down Stocks to Hold for the Next 10 Years
05.08.2026 19:18
Don't let their recent poor performances chase you away.
Pfizer Stock Slips Despite Earnings Beat and $2.5 Billion Cuts
05.08.2026 15:04
Pfizer increased its savings target and revenue outlook, but investors remained focused on patent expirations and pipeline execution.
Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts
05.08.2026 14:00
PFE raises its 2026 revenue outlook as non-COVID growth, deeper cost cuts and pipeline catalysts offset weaker COVID demand.
Pfizer Q2 Earnings Call Highlights
05.08.2026 12:04
Pfizer (NYSE:PFE) reported second-quarter 2026 revenue of $15 billion and adjusted diluted earnings per share of $0.77, with management saying both measures exceeded its internal expectations. Revenue increased 1% operationally from a year earlier, while revenue excluding COVID-19 products rose 5% o
Pfizer Hikes 2026 Sales Outlook By $500 Million On Second-Quarter Beat
04.08.2026 13:03
Pfizer stock inched higher early Tuesday on a solid second-quarter report that included a sales guidance boost.
Pfizer Covid Pill Revenue Plunges 95%. Why Earnings Are Lifting the Stock Anyway.
04.08.2026 12:53
Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand.
Pfizer’s (NYSE:PFE) Q2 CY2026: Beats On Revenue
04.08.2026 12:37
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.6% year on year to $15.03 billion. The company expects the full year’s revenue to be around $61.5 billion, close to analysts’ estimates. Its non-GAAP profit of $0.77 per share was 12.9% above analysts’ consensus estimates.